The effect of 6-gingerol on biochemical and histological parameters in cholesterol-induced nonalcoholic fatty liver disease in NMRI mice

• Autor(a) principal: Sarrafan, Asal
• Data de Publicação: 2022
• Outros Autores: Ghobeh, Maryam, Yaghmaei, Parichehreh
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Brazilian Journal of Pharmaceutical Sciences
• Texto Completo: https://www.revistas.usp.br/bjps/article/view/200755
• topic: 6-gingerol. Non-alcoholic fatty liver (NAFLD). Lipid profiles. Antioxidant enzymes. Insulin resistance. Adiponectin. Leptin.

Fatty liver contains a range of clinical symptoms, including the accumulation of fat in the liverparenchyma and it varies from a simple steatosis to non-alcoholic steatohepatitis and cirrhosis. Using natural therapies has always been a great concern for such health-related diseases. Herein, 6-gingerol, as a natural compound, was applied to treat non-alcoholic fatty liver induced in NMRI mice. The assessment included histological studies of the liver along with measurement of biochemical parameters, including insulin, glucose, adiponectin, leptin, HDL-C (high-density lipoprotein cholesterol), LDL-C (low-density lipoprotein cholesterol), VLDL-C (very low-density lipoprotein cholesterol), Aspartate transaminase (AST), Alanine aminotransferase (ALT), Alkaline phosphatase (ALP), SOD (superoxide dismutase), and catalase. The results demonstrated that treatment with 6-gingerol (800 mg/kg) modified the fatty liver indices by significantly reducing (p<0.001) the levels of triglyceride, cholesterol, LDL-C, and VLDL-C, glucose, insulin, insulin resistance, and leptin, whereas this treatment notably increased (p<0.001) the levels of liver antioxidant enzymes, HDL-c, and adiponectin. Therefore, 6-gingerol, in a dose-dependent mode, showed capability of improving non-alcoholic fatty liver and could offer a reliable remedy.